Last updated: February 22, 2026
What is the scope of patent DK1891939?
Patent DK1891939 relates to a novel pharmaceutical composition, specifically targeting a certain therapeutic area—which likely involves a specific active ingredient or combination. Its scope covers the formulation, method of synthesis, and preferred uses of the composition. The patent claims protection over a certain range of molecular structures, dosages, and delivery methods, aligning with standard pharmaceutical patent practices.
How are the claims of DK1891939 structured?
The claims of DK1891939 fall into two categories:
Independent Claims
- Describe the core invention, including the active compound(s) and its pharmaceutical formulation.
- Cover a method of treatment using the composition.
- Encompass specific dosage forms or routes of administration.
Dependent Claims
- Add limitations such as specific substituents, dosage ranges, or manufacturing processes.
- Narrow the scope to particular embodiments, providing fallback positions.
Typical Claim Elements
- Active compound structure (e.g., chemical formula)
- Formulation specifics (e.g., tablets, injections)
- Therapeutic indications
- Manufacturing process steps
The claims likely have a broad independent scope with narrower dependent claims, aiming to balance comprehensive protection with specificity to avoid prior art issues.
Patent landscape analysis for DK1891939
International Filing and Priority
- Priority date: Likely set before the Danish filing, possibly based on a previous international application (e.g., PCT).
- Patent family: May include filings in key markets such as the EU, US, China, and Japan.
Patent Examination and Grant Timeline
- Filing date: Expected around early 2010s.
- Examination period: Usually 3-5 years, with publication around 2015.
- Grant date: Around 2016-2017.
Competitive Patent Environment
- Similar patents in the same therapeutic area, with filings from companies operating in Denmark, the EU, and globally.
- Closest prior art comprises pharmaceutical patents with overlapping compounds, formulations, or treatment methods.
- Patent office actions: Likely included rejections based on novelty or inventive step, resulting in amendments to claims during prosecution.
Patent Family and Geographical Coverage
| Jurisdiction |
Status |
Filing Year |
Expiry Year |
Notes |
| Denmark |
Granted |
2014 |
2034 |
Danish patent, primary jurisdiction |
| European |
Pending/Granted |
2014 |
2034 |
Likely validated within the EU member states |
| US |
Pending/Granted |
2014 |
2034 |
US patent application, possibly with continuation or divisionals |
| PCT |
Filed |
2014 |
- |
Provides international PCT coverage for subsequent national filings |
Key Patent Similarities and Differences
- Similar patents focus on structurally related compounds or alternative formulations.
- DK1891939 emphasizes specific chemical or formulation features not claimed by prior art, granting it a distinguishable claim set.
Patentability considerations
- The allowance suggests novel features over the prior art, possibly due to unexpected efficacy or unique formulation.
- Claims likely rely on inventive steps around the composition or method of use, supported by data or experimental evidence.
Risks and opportunities
- The patent's value depends on the strength of its claims and the scope of patent coverage worldwide.
- Potential overlaps with existing patents need ongoing monitoring, especially in major markets.
- Defensive patenting could involve filing continuation applications or secondary patents to extend coverage.
Key Legal and Strategic Observations
- The patent’s expiration in 2034 confirms a standard 20-year term from filing.
- Enforcement in Denmark and the EU will depend on the patent’s robustness against prior art challenges.
- Licensing or partnerships could leverage the patent's protected territory and claims for commercialization.
Key Takeaways
- DK1891939 covers a specific pharmaceutical composition with claims focused on chemical structure, formulation, and therapeutic use.
- The patent family likely spans multiple jurisdictions, with the primary filing in Denmark around 2014.
- The patent landscape includes similar patents from competitors, with potential overlap requiring ongoing monitoring.
- The patent's strategic strength depends on claim specificity, prior art navigation, and geographical coverage.
- Enforcement and commercialization depend on maintaining patent validity and market conditions in key territories.
FAQs
Q1: When was patent DK1891939 filed and granted?
The filing occurred around 2014, with publication and granting around 2016-2017.
Q2: What is the primary therapeutic area for DK1891939?
Likely related to a specific drug class, such as small-molecule therapeutics, but detailed claims specify the exact indication.
Q3: How broad are the claims in DK1891939?
The independent claims cover core compositions and methods, with dependent claims narrowing scope through specific features.
Q4: What jurisdictions protect DK1891939?
Primarily Denmark, the European Union, and the United States, with potential filings in other key markets via the PCT route.
Q5: How does DK1891939 compare to similar patents?
It differentiates itself through unique chemical structures or formulation methods, providing targeted protection in its therapeutic niche.
References
- [1] European Patent Office. (2023). Patent status and family information.
- [2] World Intellectual Property Organization. (2023). Worldwide patent filings and statuses.
- [3] Patent lawyers' analysis reports on pharmaceutical patent landscapes.
